A recent meta-analysis reported a similar risk for the occurrence of central nervous system inflammatory disease in different types of underlying autoimmune diseases during TNF-α inhibitor therapy (monoclonal antibodies vs. TNF-α receptor IgG fusion proteins) [7]. Here, TNF is linked to autoimmune disease.